Dr. Maggie Scully is Partnership Development Director at the Frederick National Lab for Cancer Research (FNLCR), the only national lab exclusively devoted to biomedical research. She supports FNLCR’s mission to accelerate progress against cancer and AIDS by forging strategic partnerships between FNLCR scientists and external research organizations, including government, academia, industry and nonprofits. Specifically, Dr. Scully manages strategic partnerships promoting scientific exchange and training. Previously, Dr. Scully was a scientist at FNLCR’s Nanotechnology Characterization Lab. She spent over 9 years at the laboratory engineering and validating nanoparticles for drug delivery and imaging applications, predominantly for cancer indications. Dr. Scully also co-founded a start-up company dedicated to clinical translation of biopharmaceuticals for cancer, diabetes and rare diseases. The company, which is based on licensed technology from Johns Hopkins University, is currently part of a large clinical-stage parent company. Dr. Scully completed a postdoctoral fellowship at Johns Hopkins Institute for NanoBioTechnology and Johns Hopkins School of Medicine’s Department of Radiology. As a doctoral student, she was in the NIH Intramural Research Program at the National Institute of Biomedical Imaging and Bioengineering. She received her Ph.D. in Biomedical Engineering from Stony Brook University and her B.S. in Bioengineering from Lehigh University.